Skip to main content

Ervebo FDA Approval History

Last updated by Judith Stewart, BPharm on Aug 7, 2023.

FDA Approved: Yes (First approved December 19, 2019)
Brand name: Ervebo
Generic name: ebola zaire vaccine, live
Dosage form: Injection
Company: Merck
Treatment for: Ebola Zaire Disease Prophylaxis

Ervebo (ebola zaire vaccine, live) is a vaccine indicated for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older.

Development timeline for Ervebo

Aug  3, 2023Approval U.S. FDA Approves Merck’s Ervebo (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older
Dec 19, 2019Approval FDA Approves Ervebo (Ebola Zaire Vaccine, Live) for the Prevention of Disease Caused by Zaire Ebolavirus
Sep 17, 2019FDA Accepts Merck’s Biologics License Application (BLA) and Grants Priority Review for V920, the Company’s Investigational Vaccine for Ebola Zaire Virus
Nov 13, 2018Merck Begins Rolling Submission of Licensure Application for V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.